Viatris shares rise 5.09% after-hours as analysts upgrade ratings and ETF buys shares, citing regulatory progress and affordable medicine focus.

Viatris Inc. surged 5.09% in after-hours trading, driven by multiple positive developments. The stock hit a 52-week high of $12.85, with elevated volume (15.2 million shares) reflecting strong investor confidence. Institutional buying by the Burney U.S. Factor Rotation ETF, which added 222,793 shares, signaled renewed institutional interest. Analysts also raised price targets and upgraded ratings, citing recent regulatory successes and the company’s emphasis on affordable medicines. Additionally, Viatris’s presentation at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026, likely enhanced visibility and reinforced its strategic momentum. Despite concerns over declining revenues, the combination of regulatory progress, institutional support, and analyst optimism aligned with the stock’s sharp after-hours rally.